Pembrolizumab and Chemotherapy Combination Prolonged Progression-Free Survival in Patients with NSCLC with High PD-L1 Expression and Low Neutrophil-to-Lymphocyte Ratio

• मुख्य लेखकों: Jeng-Shiuan Tsai (लेखक), Sheng-Huan Wei (लेखक), Chian-Wei Chen (लेखक), Szu-Chun Yang (लेखक), Yau-Lin Tseng (लेखक), Po-Lan Su (लेखक), Chien-Chung Lin (लेखक), Wu-Chou Su (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: MDPI AG, 2022-11-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

The use of immune checkpoint inhibitors (ICIs) has provided overall survival (OS) benefits in patients with treatment-naïve advanced non-small cell lung cancer (NSCLC) without targetable driver mutations. However, studies comparing ICIs monotherapy with combination therapy either with chemotherapy o...